Switch theme
Sign up to access all valuation multiples
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
2012
n/a
LTM Revenue $209M
LTM EBITDA $33.7M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vazyme Biotech has a last 12-month revenue (LTM) of $209M and a last 12-month EBITDA of $33.7M.
In the most recent fiscal year, Vazyme Biotech achieved revenue of $192M and an EBITDA of $17.0M.
Vazyme Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vazyme Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $209M | XXX | $192M | XXX | XXX | XXX |
| Gross Profit | $146M | XXX | $134M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $33.7M | XXX | $17.0M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $6.5M | XXX | -$7.8M | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | -4% | XXX | XXX | XXX |
| Net Profit | $5.9M | XXX | -$2.5M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $16.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Vazyme Biotech's stock price is CNY 24 (or $3).
Vazyme Biotech has current market cap of CNY 9.4B (or $1.3B), and EV of CNY 7.6B (or $1.1B).
See Vazyme Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.3B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Vazyme Biotech has market cap of $1.3B and EV of $1.1B.
Vazyme Biotech's trades at 5.5x EV/Revenue multiple, and 62.3x EV/EBITDA.
Equity research analysts estimate Vazyme Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vazyme Biotech has a P/E ratio of 222.5x.
See valuation multiples for Vazyme Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 31.3x | XXX | 62.3x | XXX | XXX | XXX |
| EV/EBIT | 162.4x | XXX | -136.3x | XXX | XXX | XXX |
| EV/Gross Profit | 7.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 222.5x | XXX | -519.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -89.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVazyme Biotech's last 12 month revenue growth is 17%
Vazyme Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Vazyme Biotech's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vazyme Biotech's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vazyme Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 58% | XXX | 108% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| NetraMark | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| Bullfrog AI | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vazyme Biotech acquired XXX companies to date.
Last acquisition by Vazyme Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Vazyme Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vazyme Biotech founded? | Vazyme Biotech was founded in 2012. |
| Where is Vazyme Biotech headquartered? | Vazyme Biotech is headquartered in China. |
| Is Vazyme Biotech publicy listed? | Yes, Vazyme Biotech is a public company listed on SHG. |
| What is the stock symbol of Vazyme Biotech? | Vazyme Biotech trades under 688105 ticker. |
| When did Vazyme Biotech go public? | Vazyme Biotech went public in 2021. |
| Who are competitors of Vazyme Biotech? | Similar companies to Vazyme Biotech include e.g. Benevolent AI, NetraMark, SyntekaBio, Absci. |
| What is the current market cap of Vazyme Biotech? | Vazyme Biotech's current market cap is $1.3B |
| What is the current revenue of Vazyme Biotech? | Vazyme Biotech's last 12 months revenue is $209M. |
| What is the current revenue growth of Vazyme Biotech? | Vazyme Biotech revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Vazyme Biotech? | Current revenue multiple of Vazyme Biotech is 5.1x. |
| Is Vazyme Biotech profitable? | Yes, Vazyme Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vazyme Biotech? | Vazyme Biotech's last 12 months EBITDA is $33.7M. |
| What is Vazyme Biotech's EBITDA margin? | Vazyme Biotech's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Vazyme Biotech? | Current EBITDA multiple of Vazyme Biotech is 31.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
